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Abstract 
Fibromyalgia is believed to affect at least 2% of the population. Despite advances in the 
scientific understanding of the derangements of central and peripheral pain processing 
mechanisms in fibromyalgia, no current models of its pathophysiology account for the 
other clinical conditions associated with it such as fatigue, migraine headache, irritable 
bowel syndrome, and sleep cycle abnormalities. A neuroendocrinologic model of 
fibromyalgia is presented that accommodates both its known central and peripheral pain 
mechanisms as well as the myriad of hormonal, visceral, and psychological symptoms 
associated with that disorder. This model also provides a unifying pathophysiologic basis 
of fibromyalgia and chronic muscle pain, and offers the potential for developing new 
avenues of research and treatment for these enigmatic, frequently disabling medical 
conditions. 
Introduction 
 In 1852, Virchow first described “muscular rheumatism” 1 and five decades later 
Gowers described persons with widespread pain symptoms he termed “fibrositis” 2. The 
fibromyalgia and myofascial pain histories have overlapped, with Kelly 3 in 1945 
discussing the concept of distant referred-pain produced by “fibrositis” nodules. The 
historical overlap of these conditions is not surprising, since both the myofascial pain and 
fibromyalgia syndromes are pain conditions characterized by tender soft tissue 
(especially muscle) sites that may generate referred-pain distant to those sites.  
There are significant clinical differences between the fibromyalgia and myofascial 
pain syndromes, however. Fibromyalgia afflicts females seven times more frequently 
than males, while myofascial pain syndrome afflicts genders equally 4.  Myofascial pain 
syndrome often affects only one body region, though widespread myofascial pain has 
been described 5. In contrast, the diagnosis of fibromyalgia requires the presence of 
widespread soft tissue tenderness in multiple body regions 6. Both conditions may be 
associated with sleep disturbances, but fibromyalgia is also associated with other clinical 
conditions (Table 1) including irritable bowel syndrome, interstitial cystitis, and migraine 
headaches 7. These conditions are 4-25 times more common in individuals diagnosed 
with fibromyalgia 7. 
 Widespread body pain affects approximately 3.6% of adults in the United States 8, 
with fibromyalgia diagnosed in 5 million (2%) of adults 4. In terms of rheumatologic 
disorders, only osteoarthritis and gout 9 have higher prevalence than fibromyalgia; yet 
fibromyalgia is associated with the highest disability rate (up to 26.5%) of all 
rheumatologic disorders 10, 11.  
A Neuroendocrinologic Model of Fibromyalgia and Chronic Muscle Pain 
The sympathetic autonomic nervous system (SANS) subserves the body’s “fight 
or flight” responses to dangerous or stressful stimuli, while the parasympathetic 
autonomic nervous system (PANS) subserves its vegetative, “rest and digest” functions 
(S. Bakewell, http://www.nda.ox.ac.uk/wfsa/html/u05/u05_010.htm). Most body 
structures, including muscle, have dual sympathetic and parasympathetic innervation. As 
shown in Table 2, SANS and PANS responses have opposite physiologic effects, with the 
hypothalamus controlling the balance of those responses (D. Molavi, 
http://thalamus.wustl.edu/course/hypoANS.html).  As an example relevant to 
musculoskeletal pain, SANS activation increases resting skeletal muscle tone while 
PANS activation reduces it 12. 
The clinical conditions associated with fibromyalgia (Table 1) are postulated to 
result from imbalance or instability of the autonomic nervous system (Table 3). SANS 
abnormalities have been described for many of those conditions, including migraines 13, 
irritable bowel syndrome 14, interstitial cystitis 15, endometriosis 16, idiopathic urethritis 
17, chronic prostatitis 18, and temporomandibular joint pain 19. Thus, abnormal regulation 
of SANS/PANS outflow balance by the hypothalamus could result in these clinical 
conditions seen in fibromyalgia patients. The circadian rhythms of sleep 20, appetite 
regulation 21, mood 22, and temperature 23 also are regulated at the hypothalamic level; 
and the abnormalities of those physiologic functions often described by fibromyalgia 
patients are also consistent with hypothalamic dysfunction.  
Though the insular cortex is believed to be mainly a viscerosensory structure, the 
right insular cortex is believed to provide sympathetic outflow to the hypothalamus and 
the left insular cortex its parasympathetic outflow 24. The orbitofrontal and medial 
prefrontal cortex areas of the limbic system have direct anatomic input to the 
hypothalamus, allowing emotions to directly influence autonomic balance there 25. The 
amygdala serves to integrate behavioral and autonomic responses from the 
somatosensory cortex and limbic system structures including the medial prefrontal cortex, 
orbitofrontal cortex, cingulate gyrus, hippocampus, anterior thalamic nuclei, and medial 
thalamic nuclei 26. The amygdala is thought to have inhibitory influence on the 
hypothalamus to attenuate SANS output 27. These thalamic and cortical influences on the 
hypothalamus are demonstrated in Figure 1. 
Hypothalamic SANS output arises from its posterolateral nuclei that ultimately 
innervate the interomediolateral nuclei of the spinal cord, while its PANS output arises 
from its anteromedial nuclei that ultimately course to peripheral structures via the vagus 
nerve (D. Molavi, http://thalamus.wustl.edu/course/hypoANS.html). The hypothalamus 
also regulates the release of cortisol and norepinephrine through the hypothalamic-
pituitary-adrenal (HPA) axis, which provides systemic SANS activation with slower 
onset and longer duration (D. Molavi, http://thalamus.wustl.edu/course/hypoANS.html).  
Further, hypothalamic output regulates brainstem structures (rostroventral medulla, 
periaqueductal gray, and locus ceruleus) whose descending pathways to the dorsal horn 
of the spinal cord modulate pain transduction in nociceptive neurons there, as shown in 
Figure 1 28. 
The systemic norepinephrine release via the HPA axis, accentuated SANS tone 
through hypothalamic output to the interomediolateral cells of the spinal cord, and 
reduced descending pain inhibition at the spinal cord level are then postulated in this 
neuroendocrinologic model to produce sensitization of primary nociceptors in 
fibromyalgia patients. Clinical research supporting this includes documentation that 
fibromyalgia patients have elevated plasma catecholamine levels, which are associated 
with hyperalgesia 29,30. Approximately 8% of spinal nerve fibers are postganglionic 
sympathetic fibers 31, which also invest the arteries that accompany spinal nerves and 
their branches to the extremities 32 (H. Gray, http://www.bartleby.com/107/214.html). 
Neurogenic inflammation is a physiologic phenomenon 33 in which efferent 
outflow from the spinal cord (dorsal root reflexes) causes nociceptive C-fibers to release 
substance P (sP), calcitonin gene related peptide (cGRP) and somatostatin from their 
terminal axons. These substances then cause local vasculature (plasma), platelets, and 
macrophages to release bradykinin, histamine, and serotonin, which serve to activate 
those nociceptive neurons 34, as illustrated in Figure 2. Thus, a local positive feedback 
loop is produced as neurogenic inflammation ultimately produces release of substances 
from the terminal axons that activate the primary nociceptors. Efferent or systemic SANS 
activation can further sensitize these nociceptive neurons (Figures 1 and 2). The 
abnormally high metabolic activity seen in the thalamus, amygdala, hippocampus, 
cingulate gyrus, and other limbic system structures in fibromyalgia patients 35 is 
consistent with abnormal central nervous system (CNS) autonomic efferent activity 
contributing to nociceptor sensitization and neurogenic inflammation peripherally. 
Psychological stress alone can cause degranulation of mast cells (many of which are 
estrogen receptor positive) to initiate neurogenic inflammation 36,37, which may help 
explain the predominance of fibromyalgia in females. Neurogenic inflammation causes 
local edema (fibromyalgia nodules) and tenderness without histological presence of 
inflammatory cells 38. Continuing activation of dorsal root reflexes and propriospinal 
pathways produces ascending and descending sensitization of nociceptors in adjacent 
spinal levels, providing a mechanism for the spread of tender regions to increasingly 
larger areas of the body 34. This is consistent with Shah’s findings 39 that trigger points 
have markedly increased concentrations of inflammatory mediators, but also that muscle 
sites distant from the trigger points in those subjects have lesser elevations of these 
inflammatory mediators (higher than normal), suggesting systemic nervous system 
sensitization as predicted by this neuroendocrinologic model. Efferent output of these 
sensitized primary nociceptors also leads to activation of wide dynamic range neurons in 
the deeper lamina of the spinal cord, which have wider cutaneous receptive fields and 
visceral sensory input.  
Primary nociceptors relay information through the lateral spinothalamic tract to 
the lateral thalamus then on to the somatosensory cortex to localize painful stimuli, while 
wide dynamic range neurons send information through the paleospinothalamic tract to the 
anterior and medial thalamus then on to limbic system structures that subserve the 
emotional and behavioral reactions to painful stimuli 34. These ascending pathways are 
largely anatomically independent of each other. As shown in Figure 1, abnormal 
activation of the neospinothalamic and paleospinothalamic pathways then forms the final 
link in a positive feedback loop to produce excessive activation of the thalamus, 
neocortex, and limbic system structures that regulate autonomic balance centrally. 
Abnormal activation of hypothalamic and limbic system structures provides an anatomic 
substrate that could account for the excessive behavioral reactions to noxious stimuli seen 
in chronic pain patients 40,41. This may represent the central mechanism of the lowering 
of pain perception threshold (“thermostat”) in chronic pain patients, which in its extreme 
progresses from hyperpathia to allodynia.  
There is also pharmacologic evidence that supports this neurogenic model of 
fibromyalgia. Drugs that demonstrate the most efficacy for treating fibromyalgia are in 
the anti-convulsant (e.g. pregabalin) and anti-depressant (e.g. duloxitene) classes, which 
act on the central and peripheral nervous systems. Fibromyalgia symptoms are relatively 
resistant to opioids and anti-inflammatory drugs, which are efficacious for treating 
musculoskeletal pain conditions. 
 
Discussion 
 Functional MRI and neurophysiologic studies have demonstrated objective 
evidence of abnormal central nervous system pain sensitization in patients with 
fibromyalgia, even though its cause remains enigmatic. The recent work of Shah 39 
demonstrates physiologic evidence of similar central nervous system sensitization in 
myofascial pain syndrome.  
 Though both fibromyalgia and myofascial pain syndrome share the phenomenon 
of tender muscular regions, only fibromyalgia is associated with other conditions such as 
chronic headaches, irritable bowel syndrome, interstitial cystitis, and temporomandibular 
joint pain syndrome. Clinical and experimental evidence of the role of neurogenic 
inflammation and autonomic nervous system dysfunction in those disorders continues to 
accumulate. 
 This neuroendocrinologic model of fibromyalgia provides an anatomically and 
physiologically based conceptualization of the central and peripheral physiologic 
mechanisms that can produce the widespread muscular tenderness and visceral 
dysfunction seen clinically in fibromyalgia patients. The model integrates the known 
clinical and experimental findings of abnormal hypothalamic- pituitary- adrenal axis 
activation and abnormal and/or unstable autonomic nervous system balance that are 
associated with widespread pain and visceral dysfunction in fibromyalgia patients (Figure 
3).  
 The clinical syndrome of fibromyalgia, then, can be initiated by excessive 
noxious input at any point along this loop by a wide variety of causes. Excessive 
psychological trauma or stress is postulated to initiate this positive feedback loop 
centrally at the level of the paleocortex (limbic system). Visceral injury or recurrent insult 
(myocardial infarct, “leaky gut syndrome” after antibiotic administration, recurrent 
prostatitis) then initiates this positive feedback loop through severe or recurrent abnormal 
visceral nociceptor activation.  Similarly, severe and or recurrent musculoskeletal or 
peripheral nerve injuries can activate this positive feedback loop through A-delta and C-
fiber activation with neurogenic inflammation. 
 
Conclusion 
 The model of fibromyalgia presented herein as dysfunction of the autonomic 
nervous system with sensitization of central nervous system nociception can unify the 
multiple clinical findings noted in that disorder including cognitive impairment, 
depression, sleep disturbance, widespread pain, and organ dysfunction such as irritable 
bowel syndrome and interstitial cystitis. This model offers a novel view of the 
pathogenesis of this enigmatic syndrome that causes substantial morbidity and not 
infrequently disability, and may lead to new avenues of treatment. 
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Table 1. Clinical Conditions Associated with Fibromyalgia 
Clinical Condition % fibromyalgia patients % general populaton 
Chronic headache 50% 5% 
Dysmenorrhea 60% 15% 
Endometriosis 15% 2% 
Interstitial cystitis 25% <1% 
Irritable bladder/ urethra 15% <1% 
Irritable bowel syndrome 60% 10% 
Mitral valve prolapse 75% 15% 
Multiple chemical sensitivities 40% 5% 
Restless legs syndrome 30% 2% 
TMJ syndrome 25% 5% 
 
Table 2. Autonomic Nervous System and Its Clinical Effects 
 
SANS Effects PANS Effects 
“fight or flight” “rest and digest” 
↑ alertness/vigilance ↓ alertness/vigilance 
↑ heart rate and contractility ↓ heart rate and contractility 
↑ breathing rate with 
bronchodilitation 
↓ breathing rate with 
bronchoconstriction 
↑ cardiac and skeletal  
muscle blood flow 
↓ cardiac and skeletal  
muscle blood flow 
↓ gut blood flow ↑ gut blood flow 
↓ cutaneous blood flow ↑ cutaneous blood flow 
↑ blood sugar ↓ blood sugar 
↑ temperature ↓ temperature 
↓ gut contractility ↑ gut contractility 
↓ bladder contractility ↑ bladder contractility 
↓salivation ↑ salivation 
↓lacrimation ↑ lacrimation 
↓digestion ↑ digestion 
 
SANS= sympathetic autonomic nervous system 
PANS= parasympathetic autonomic nervous system
Table 3. Autonomic Nervous System Imbalance in Fibromyalgia (relative degree of tonus)  
 
Clinical Condition SANS PANS 
Migraine ↑ initial phase ↑later phase 
IBS, diarrhea predominant ↓ ↑ 
IBS, constipation predominant ↑ ↓ 
Interstitial Cystitis ↑ ↑ 
Raynaud’s-like phenomenon ↑ ↓ 
Endometriosis ↑ ↓ 
Aseptic Prostatitis ↑ ↓ 
Idiopathic Urethritis ↑ ↓ 
Skeletal Muscle Tone ↑ - 
 
IBS= irritable bowel syndrome 
SANS= sympathetic autonomic nervous system 
PANS= parasympathetic autonomic nervous system  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Legends 
 
Figure 1. Detailed Neurophysiology of Positive Feedback Loop in Fibromyalgia 
 
Figure 2. Peripheral Sensitization Mechanisms 
 
Figure 3. Simplified Positive Feedback Loop in Fibromyalgia 
 



